OmniAb, Inc. (OABI)

NASDAQ: OABI · Real-Time Price · USD

4.610

-0.050 (-1.07%)

Oct 26, 2026, 4:00 PM EDT - Market closed

Market Cap	670.25M +185.6%
Revenue (ttm)	38.46M +67.0%
Net Income	-44.27M
EPS	-0.35
Shares Out	145.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	971,627
Open	4.660
Previous Close	4.660
Day's Range	4.530 - 4.720
52-Week Range	1.300 - 5.430
Beta	1.37
Analysts	Strong Buy
Price Target	8.33 (+80.69%)
Earnings Date	Oct 30, 2026

About OABI

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company’s technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners’ drug development efforts. Its OmniAb platform’s Biological Intelligence powers the immune systems of its proprietary and engineered transgenic anim... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2012

Employees 89

Stock Exchange Nasdaq

Ticker Symbol OABI

Website https://www.omniab.com

Full Company Profile

Financial Performance

In 2025, OmniAb's revenue was $18.67 million, a decrease of -29.27% compared to the previous year's $26.39 million. Losses were -$64.78 million, 4.43% more than in 2024.

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for OABI stock is "Strong Buy." The 12-month stock price target is $8.33, which is an increase of 80.69% from the latest price.

Price Target

$8.33

(80.69% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

OmniAb to Participate in Upcoming Investor Conferences in November

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, toda...

Other symbols: OABI

5 hours ago - Business Wire

OmniAb Transcript: LD Micro 20th Annual Main Event Conference

The platform pairs transgenic antibody discovery with AI screening, supporting 425 active programs and 34 clinical-stage drugs. xPloration sales are forecast to double in 2027 and again in 2028, while current-year revenue guidance is $32 million–$36 million.

6 days ago - Transcripts

OmniAb to Report Third Quarter 2026 Financial Results on October 30

Other symbols: OABI

12 days ago - Business Wire

OmniAb price target raised to $6 from $4 at StoneX

StoneX analyst Robert Wasserman raised the firm’s price target on OmniAb (OABI) to $6 from $4 and keeps a Buy rating on the shares after the company held its first…

19 days ago - TheFly

OmniAb Transcript: Investor And Anlayst Day 2026

A maturing royalty pipeline, new peptide platform and general-market launch of xPloration broaden growth engines. 2026 guidance was reaffirmed, with xPloration revenue forecast to double annually in 2027 and 2028.

20 days ago - Transcripts

OmniAb Slides: FY 2026

OmniAb has posted slides in relation to its FY 2026 quarterly earnings report, which was published on October 6, 2026.

20 days ago - Filings

OmniAb Press release: FY 2026

OmniAb issued a press release on October 6, 2026, disclosing material business information to investors.

20 days ago - Filings

OmniAb highlights partner pipeline, xPloration plans, introduces OmniTides

OmniAb (OABI) hosts its Investor & Analyst Day in Emeryville, CA. With a full presentation agenda, the event highlights recent partner developments, the broader roll out of the xPloration platform,…

20 days ago - TheFly

OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day

Other symbols: OABI

20 days ago - Business Wire

OmniAb to Host Investor & Analyst Day on October 6, 2026

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #Antibody--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, ...

Other symbols: OABI

6 weeks ago - Business Wire

OmniAb to Participate in Upcoming Investor Conferences

Other symbols: OABI

2 months ago - Business Wire

OmniAb raises FY26 cash and equivalents view to $49M-$53M vs. $37M-$41M

OmniAb (OABI) raised its FY26 cash and cash equivalents financial guidance following recent technology licensing activity. “Recent business development and licensing activity has enabled us to again r...

2 months ago - TheFly

OmniAb Raises 2026 Financial Guidance

Other symbols: OABI

2 months ago - Business Wire

OmniAb announces collaboration and license agreement with Eli Lilly

OmniAb (OABI) announced a global collaboration and license agreement with Eli Lilly and Company (LLY) for a new ion channel program. The collaboration leverages OmniAb’s technology platform and expert...

Other symbols: LLY

2 months ago - TheFly